Fresenius | FRE - Des Atouts





Des Atouts Changement Date
Akzo Nobel EUR 15.49B 1.53B 2026-03
Alcon AG USD 31.62B 64M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
BASF EUR 76.17B 267M 2025-12
Bayer EUR 107.94B 3.4B 2026-03
Beiersdorf EUR 12.76B 166M 2025-12
DaVita Healthcare Partners USD 17.5B 19.26M 2026-03
Demant DKK 39.07B 6.43B 2025-12
E.ON EUR 117.22B 6.53B 2026-03
Essilor EUR 63.9B 1.97B 2025-12
Fresenius EUR 41.4B 1.07B 2025-12
Fresenius Medical Care EUR 31.47B 465.26M 2026-03
Getinge SEK 63.92B 4.3B 2024-12
Givaudan CHF 11.86B 587M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
GN Store Nord DKK 28.56B 671M 2026-03
GRIFOLS EUR 20.08B 366M 2026-03
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Lonza CHF 18.97B 164M 2025-12
Merck EUR 53.07B 1.54B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Philips EUR 27.27B 322M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
RWE EUR 116.76B 15.05B 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Smith & Nephew USD 10.69B 150M 2025-12